Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA347594
Max Phase: Preclinical
Molecular Formula: C28H38N2O5
Molecular Weight: 482.62
Molecule Type: Small molecule
Associated Items:
ID: ALA347594
Max Phase: Preclinical
Molecular Formula: C28H38N2O5
Molecular Weight: 482.62
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccccc1)CC(=O)O)C(C)(C)C)c1ccccc1
Standard InChI: InChI=1S/C28H38N2O5/c1-28(2,3)25(27(34)29-23(19-35-4)21-15-9-6-10-16-21)30-26(33)22(18-24(31)32)17-11-14-20-12-7-5-8-13-20/h5-10,12-13,15-16,22-23,25H,11,14,17-19H2,1-4H3,(H,29,34)(H,30,33)(H,31,32)/t22-,23-,25-/m1/s1
Standard InChI Key: FYHSMVNHGKEDAV-VDKIKQQVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 482.62 | Molecular Weight (Monoisotopic): 482.2781 | AlogP: 4.14 | #Rotatable Bonds: 13 |
Polar Surface Area: 104.73 | Molecular Species: ACID | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.51 | CX Basic pKa: | CX LogP: 4.49 | CX LogD: 1.70 |
Aromatic Rings: 2 | Heavy Atoms: 35 | QED Weighted: 0.40 | Np Likeness Score: 0.38 |
1. Fray MJ, Burslem MF, Dickinson RP.. (2001) Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality., 11 (4): [PMID:11229773] [10.1016/s0960-894x(00)00719-8] |
2. Verma RP, Hansch C.. (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs., 15 (6): [PMID:17275314] [10.1016/j.bmc.2007.01.011] |
Source(1):